Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTV01E-1 Immunogenicity and Safety in Adults
NCT05522829Phase 2Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of SCTV01E-1 in coronavirus disease 2019 (COVID-19), sponsored by Sinocelltech Group Limited. Status: unknown.
02
Drugs
SCTV01E-1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05522829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522829.